Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
SNBL and Tasso, Inc. to Establish Joint Venture in Japan
SNBL’s Subsidiary, SNLD, Announces its Abstract Accepted at the Upcoming 77th American Academy of Neurology (AAN) 2025 Annual Meeting
SHIN NIPPON BIOMEDICAL, The Current Fiscal Year Ordinary Profit Revised Upward by 10%
Notice Regarding Revisions of the Earnings Forecasts for the Full-Year of the Fiscal Year Ending March 31, 2025
Presentation Materials for the Third Quarter of the Fiscal Year Ending March 31, 2025
Consolidated Financial Results for the Nine Months of the Fiscal Year Ending March 31, 2025 (Under Japanese GAAP)
SNBL Integrated Report 2024 part2
SNBL Integrated Report 2024 part1
SNBL Signs Mizuho Eco Finance Agreement with Mizuho Bank
Dr. Ryoichi Nagata, President of SNBL, Awarded Bhutan’s Prestigious National Order of Merit Gold Medal for His Distinguished Services
SNBL’s Subsidiary, Satsuma Pharmaceuticals Receives FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine
Corporate Governance Report
SNBL Invests in WOOJUNG BIO Inc. in Korea
U.S.-based Plug and Play, LLC Signs Partnership Agreement with a Joint Fund by SNBL and SBI Holdings, Inc.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., First Half Ordinary Profit Decreases by 51%, July-September Ordinary Profit Decreases by 21%
Presentation Materials for the First Six Months of the Fiscal Year Ending March 31, 2025
Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2025 (Under Japanese GAAP)
Notice Regarding Differences between Consolidated Financial Forecasts and Actual Results for the Six Months Ended September 30, 2024
Notice Regarding Distribution of Interim Dividends from Retained Earnings
SNBL's Subsidiary Satsuma Pharmaceuticals Resubmits New Drug Application for STS101 for Acute Treatment of Migraine With or Without Aura